GLP-1 and Thyroid Cancer: What Studies Say

GLP-1 drugs do not appear to increase risk of most cancers. A 2025 meta-analysis of 50 randomized controlled trialsfound no link between GLP-1 receptor agonist use and cancer risk for majority of cancer types studied. The one exception is a small signal for thyroid cancer, which we'll go through in detail below.

If you've seen boxed warning on Ozempic, Wegovy, Mounjaro, or Zepbound and wondered whether these drugs can give you cancer, that's a reasonable concern. The warning is there because of rodent studies, not because of confirmed cancer cases in humans. But question deserves a careful, specific answer rather than a blanket reassurance.

What is boxed warning about?

Every GLP 1 drug on market carries a boxed warning about thyroid C cell tumors. This is most serious type of FDA warning. It's based on animal studies, specifically in rats and mice, where GLP 1 drugs caused a type of thyroid cancer called medullary thyroid carcinoma (MTC) when given at high doses for long periods.

Rats have a lot of GLP 1 receptors on their thyroid C cells. Humans have far fewer. That biological difference is why findings in rodents haven't translated directly to humans. But FDA included boxed warning as a precaution because animal signal was strong and consistent.

The practical result of this warning is that GLP 1 drugs should not be used by anyone who has a personal or family history of medullary thyroid cancer, or a rare condition called multiple endocrine neoplasia syndrome type 2 (MEN2). For everyone else, warning doesn't mean you'll get thyroid cancer. It means FDA wants you and your doctor to know about animal data.

Do GLP 1 drugs cause thyroid cancer in humans?

The evidence so far says: probably not, but the question isn't fully settled.

Multiple large studies have looked at this. A 2025 review in Journal of Clinical Investigation that analyzed meta analyses and real world cohort data found that epidemiologic evidence has generally failed to show a persistent, excess risk for most cancers in people using GLP 1 drugs. For tirzepatide specifically, a meta analysis found no excess cancer risk across 15 cancer types compared to controls.

But Silverii meta analysis of 50 randomized controlled trials did detect a statistically modest increase in thyroid cancer risk with GLP-1 drugs (odds ratio 1.55). The researchers noted a fragility index of 1, which means just one additional thyroid cancer case in comparison group would have made finding statistically nonsignificant. That's a very thin margin.

A large Scandinavian cohort study published in BMJ in 2024 found a slightly higher rate of all thyroid cancers in GLP-1 users who took drugs for one to three years. But a separate multisite international study covering nearly 100,000 GLP 1 users found no increased risk. And a TriNetX study with nearly 90,000 patients followed for up to a decade also found no association.

So picture is mixed. Most of high quality evidence says no increased risk. A few studies show a small signal. None of them are definitive. If you want to read about how this question applies to Mounjaro specifically, we cover that in has anyone gotten thyroid cancer from Mounjaro.

There's also a detection bias issue worth understanding. People on GLP 1 drugs see their doctors more often than people not on medications. More doctor visits means more blood tests, more physical exams, and more incidental findings. Some of thyroid nodules found in GLP-1 users may have been there all along and were only discovered because patient was being monitored more closely.

What about tirzepatide and cancer specifically?

This is a common search because tirzepatide (Mounjaro, Zepbound) is newest and most potent drug in class, and people want to know if its dual agonist mechanism carries additional cancer risk.

The data so far is reassuring. The JCI review noted that a meta analysis of tirzepatide trials found no excess risk for any of 15 cancer types examined: breast, colon, gastric, lung, lymphoma, ovarian, pancreatic, prostate, renal, skin, squamous cell, thyroid, bladder, uterine, and glioblastoma. In fact, patients on highest dose of tirzepatide had lowest cancer risk in analysis.

This doesn't mean tirzepatide is proven cancer free over long term. The clinical trials typically lasted 40 to 72 weeks, which is too short to detect cancers that take years to develop. But short term safety data is clean. If you have questions about tirzepatide side effects and cancer specifically, that article goes into more detail.

Do GLP 1 drugs cause pancreatic cancer?

No. This was a concern that got a lot of attention about a decade ago. Early case reports of pancreatitis and a handful of pancreatic cancer cases in patients on exenatide and liraglutide led to FDA investigations and media coverage.

Since then, every large clinical trial that has tracked pancreatic cancer as an outcome has found no increased risk. The SELECT trial (17,604 patients, 40 months of follow up) found no difference in pancreatic cancer rates between semaglutide and placebo. The LEADER trial for liraglutide found same. The SURMOUNT trials for tirzepatide found same.

The JCI review stated directly that concerns about GLP 1 drugs raising risk of acute pancreatitis and pancreatic cancer have been dispelled by long term clinical trial data.

GLP-1 drugs can cause pancreatitis in rare cases, which is a different question from cancer. Pancreatitis is inflammation. Cancer is uncontrolled cell growth. Having pancreatitis does not mean you'll develop pancreatic cancer. We break down what's known about GLP 1 drugs and pancreatic cancer risk in GLP 1 and pancreatic cancer.

What about other cancers?

The Silverii meta analysis found a statistically modest signal for colorectal cancer (odds ratio 1.27), but only in shorter term trials. This finding wasn't consistent across longer studies, which makes it less concerning. It may reflect confounding factors rather than a true drug effect.

For uterine cancer, same analysis found a possible protective effect in trials enrolling people with obesity. GLP 1 drugs reduced odds of uterine cancer by about 76% compared to placebo in those trials. Obesity is a strong risk factor for uterine cancer, so this makes biological sense: by helping patients lose weight, drug may reduce hormonal and inflammatory environment that drives uterine cancer growth.

A large retrospective study found that GLP-1 drug use was associated with a lower risk of gallbladder cancer and liver cancer compared to insulin. Again, this may be partly explained by weight loss and improvements in fatty liver disease, both of which are independent risk factors for these cancers.

The broader pattern is that GLP-1 drugs don't increase risk of most cancers and may reduce risk of some obesity related cancers. The thyroid signal is only consistent concern, and even that remains small and unconfirmed in largest studies.

Does weight loss itself reduce cancer risk?

Yes. Obesity is linked to at least 13 types of cancer. Excess body fat drives chronic inflammation, insulin resistance, and elevated hormone levels that promote cancer cell growth. Losing weight reduces all three of those drivers.

A person with obesity who loses 10% to 20% of their body weight is lowering their risk of breast cancer, colon cancer, endometrial cancer, kidney cancer, and others. The weight loss itself is protective regardless of how it's achieved, whether through medication, surgery, or lifestyle changes.

This matters for GLP 1 cancer risk discussion because drugs are being used in a population (people with obesity) that already has an elevated baseline cancer risk. Any assessment of whether drug increases cancer risk needs to be weighed against cancer risk reduction that comes from weight loss drug produces.

What should you do with this information?

If you don't have a personal or family history of medullary thyroid cancer or MEN2, current evidence does not give you a reason to avoid GLP 1 drugs because of cancer risk. The data from clinical trials, meta analyses, and real world cohort studies is mostly reassuring.

If you're concerned, talk to your doctor about your specific cancer history and family history. They can help you decide whether any additional monitoring makes sense for your situation.

For most patients, cardiovascular, metabolic, and weight related benefits of GLP 1 drugs far outweigh theoretical cancer risk, which remains unproven for most cancer types and very small even for thyroid cancer.

Your doctor can check your thyroid function with a simple blood test and physical exam. If you develop a lump in your neck, difficulty swallowing, hoarseness, or persistent neck pain while on a GLP 1 drug, let your doctor know. These symptoms don't mean you have cancer, but they should be evaluated.

We cover GLP-1 and thyroid cancer risk question in more depth in a separate article for readers who want to dig further into thyroid specific data.